<DOC>
	<DOC>NCT02526641</DOC>
	<brief_summary>Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the hepatic venous pressure gradient (HVPG), and metabolic liver function determined by the galactose elimination capacity (GEC) test and the functional hepatic nitrogen clearance (FHNC).</brief_summary>
	<brief_title>Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Hypertension, Portal</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Chronic hepatitis C genotype 1 or 4 patients initiating the new AbbVie treatment (paritaprevir, ritonavir, ombitasvir og dasabuvir sammen med ribavirin) ChildPugh A liver cirrhosis Severe liver dysfunction ChildPugh klasse BC Life expectancy less than 6 months planned liver transplantation or TIPS procedure within 6 months noncompliance to treatment or study procedures allergy to the DAA drugs used (paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin) pregnancy or expected pregnancy during the study (anticonception has to be used) breast feeding portal vein thrombosis liver cancer or other malignancies alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Direct acting antiviral treatment</keyword>
	<keyword>sCD163</keyword>
	<keyword>Portal hypertension</keyword>
	<keyword>Metabolic liver function</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>